Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071489757> ?p ?o ?g. }
- W2071489757 endingPage "168" @default.
- W2071489757 startingPage "162" @default.
- W2071489757 abstract "Polymyositis and dermatomyositis are inflammatory muscular diseases of unknown cause. Many interventions are available to treat patients with these conditions including corticosteroids, immunosuppressive drugs, plasmapheresis, and total body irradiation. However, these therapies are not always effective, and they may be associated with certain serious side effects. An attempt was made to evaluate the efficacy of polyvalent intravenous immunoglobulin (IVIG) in patients with polymyositis or dermatomyositis refractory to traditional treatment.Twenty patients (16 women and 4 men; mean age 43 [16 SD] years), 14 with chronic refractory polymyositis and six with dermatomyositis, received high doses of IVIG because of the failure of traditional treatments (prednisone [19], methotrexate [10], azathioprine [6], cyclophosphamide [3], cyclosporine [3], chlorambucil [1], plasmapheresis [8], lymphopheresis [1], and total body irradiation [1]). In one patient with positive results on picornavirus serologic testing, IVIG was the first treatment choice. IVIG therapy was given with prednisone in 15 patients, with methotrexate in six patients, and with plasmapheresis in one patient. There were no changes in treatment in the 2 months before the introduction of IVIG therapy and no increases in dose during this treatment. Preparations of polyvalent human intravenous gammaglobulins with increased intact immunoglobulin G were used. Thirteen patients received 1 g/kg daily for 2 days each month, and seven patients received 0.4 g/kg daily for 5 days each month. The mean duration of treatment was 4 months.Clinical assessment, which consisted of the measurement of proximal muscle power, and biochemical studies were carried out before each treatment period. Significant clinical improvement was noted in 15 of the 20 patients. Mean muscle power estimated for the 20 patients before and after IVIG therapy was statistically significantly reduced (p less than 0.01). Eighteen patients showed biochemical improvement, and two patients with normal initial serum creatine kinase levels showed clinical improvement. Mean creatine kinase levels for the 20 patients during IVIG therapy showed a statistically significant decrease from the first IVIG perfusions (p less than 0.01). Side effects of IVIG therapy were noted in four patients; however, these effects were mild. During IVIG therapy, steroid doses were significantly reduced from the second or the third IVIG infusion (p less than 0.05).IVIG is an efficacious new therapy for polymyositis and dermatomyositis and should play a role in the treatment of these diseases, replacing or reducing steroid and immunosuppressive medications." @default.
- W2071489757 created "2016-06-24" @default.
- W2071489757 creator A5012411486 @default.
- W2071489757 creator A5019648580 @default.
- W2071489757 creator A5030129204 @default.
- W2071489757 creator A5053505571 @default.
- W2071489757 creator A5060820412 @default.
- W2071489757 creator A5062440158 @default.
- W2071489757 creator A5066076898 @default.
- W2071489757 creator A5085350084 @default.
- W2071489757 date "1991-08-01" @default.
- W2071489757 modified "2023-10-16" @default.
- W2071489757 title "Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients" @default.
- W2071489757 cites W1569086099 @default.
- W2071489757 cites W184510336 @default.
- W2071489757 cites W1963990658 @default.
- W2071489757 cites W1969703956 @default.
- W2071489757 cites W1969750186 @default.
- W2071489757 cites W1971021669 @default.
- W2071489757 cites W1977335054 @default.
- W2071489757 cites W1978602698 @default.
- W2071489757 cites W1979820418 @default.
- W2071489757 cites W1981604658 @default.
- W2071489757 cites W1984855350 @default.
- W2071489757 cites W1987003691 @default.
- W2071489757 cites W1991676572 @default.
- W2071489757 cites W1998766811 @default.
- W2071489757 cites W2007641665 @default.
- W2071489757 cites W2010176673 @default.
- W2071489757 cites W2022134162 @default.
- W2071489757 cites W2026509111 @default.
- W2071489757 cites W2039126449 @default.
- W2071489757 cites W2050622532 @default.
- W2071489757 cites W2054178361 @default.
- W2071489757 cites W2059500910 @default.
- W2071489757 cites W2079824024 @default.
- W2071489757 cites W2080981505 @default.
- W2071489757 cites W2085548839 @default.
- W2071489757 cites W2088654954 @default.
- W2071489757 cites W2088678446 @default.
- W2071489757 cites W2088802548 @default.
- W2071489757 cites W2314311014 @default.
- W2071489757 cites W2316519689 @default.
- W2071489757 cites W2329991082 @default.
- W2071489757 cites W2408450211 @default.
- W2071489757 cites W3028321621 @default.
- W2071489757 cites W3197059284 @default.
- W2071489757 doi "https://doi.org/10.1016/0002-9343(91)90009-m" @default.
- W2071489757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1714235" @default.
- W2071489757 hasPublicationYear "1991" @default.
- W2071489757 type Work @default.
- W2071489757 sameAs 2071489757 @default.
- W2071489757 citedByCount "230" @default.
- W2071489757 countsByYear W20714897572012 @default.
- W2071489757 countsByYear W20714897572013 @default.
- W2071489757 countsByYear W20714897572014 @default.
- W2071489757 countsByYear W20714897572015 @default.
- W2071489757 countsByYear W20714897572016 @default.
- W2071489757 countsByYear W20714897572017 @default.
- W2071489757 countsByYear W20714897572018 @default.
- W2071489757 countsByYear W20714897572019 @default.
- W2071489757 countsByYear W20714897572020 @default.
- W2071489757 countsByYear W20714897572021 @default.
- W2071489757 countsByYear W20714897572022 @default.
- W2071489757 countsByYear W20714897572023 @default.
- W2071489757 crossrefType "journal-article" @default.
- W2071489757 hasAuthorship W2071489757A5012411486 @default.
- W2071489757 hasAuthorship W2071489757A5019648580 @default.
- W2071489757 hasAuthorship W2071489757A5030129204 @default.
- W2071489757 hasAuthorship W2071489757A5053505571 @default.
- W2071489757 hasAuthorship W2071489757A5060820412 @default.
- W2071489757 hasAuthorship W2071489757A5062440158 @default.
- W2071489757 hasAuthorship W2071489757A5066076898 @default.
- W2071489757 hasAuthorship W2071489757A5085350084 @default.
- W2071489757 hasConcept C121332964 @default.
- W2071489757 hasConcept C126322002 @default.
- W2071489757 hasConcept C141071460 @default.
- W2071489757 hasConcept C142424586 @default.
- W2071489757 hasConcept C159654299 @default.
- W2071489757 hasConcept C203014093 @default.
- W2071489757 hasConcept C2776694085 @default.
- W2071489757 hasConcept C2776755627 @default.
- W2071489757 hasConcept C2776760755 @default.
- W2071489757 hasConcept C2778720950 @default.
- W2071489757 hasConcept C2778751314 @default.
- W2071489757 hasConcept C2778842783 @default.
- W2071489757 hasConcept C2778880498 @default.
- W2071489757 hasConcept C2779134260 @default.
- W2071489757 hasConcept C2779387793 @default.
- W2071489757 hasConcept C2781059491 @default.
- W2071489757 hasConcept C2909916134 @default.
- W2071489757 hasConcept C71924100 @default.
- W2071489757 hasConcept C79162176 @default.
- W2071489757 hasConcept C87355193 @default.
- W2071489757 hasConcept C90924648 @default.
- W2071489757 hasConceptScore W2071489757C121332964 @default.
- W2071489757 hasConceptScore W2071489757C126322002 @default.
- W2071489757 hasConceptScore W2071489757C141071460 @default.